Weekly Investment Analysts’ Ratings Changes for Brainsway (BWAY)

Brainsway (NASDAQ: BWAY) has recently received a number of price target changes and ratings updates:

• 8/2/2026 – Brainsway was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/25/2026 – Brainsway was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/24/2026 – Brainsway had its “buy” rating reaffirmed by New Street Research.
• 7/21/2026 – Brainsway had its “buy (b-)” rating reaffirmed by Weiss Ratings.
• 7/20/2026 – Brainsway is now covered by BTIG Research. They set a “buy” rating and a $18.00 price target on the stock.
• 7/17/2026 – Brainsway had its “buy” rating reaffirmed by HC Wainwright. They now have a $14.00 price target on the stock.
• 7/13/2026 – Brainsway was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/2/2026 – Brainsway had its “buy” rating reaffirmed by HC Wainwright. They now have a $17.00 price target on the stock.
• 6/15/2026 – Brainsway had its “buy” rating reaffirmed by HC Wainwright. They now have a $17.00 price target on the stock.
• 6/13/2026 – Brainsway was upgraded by Wall Street Zen from “hold” to “buy”.

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.